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Prior Presentation 
Presented in part at the 2018 Annual Meeting of the European Society of Medical Oncology, 
Munich, Germany.  
 
Translational Relevance 
While treatment of locally advanced rectal cancer with neoadjuvant chemotherapy is efficacious and has 
become more commonplace, our study demonstrates resistance to standard neoadjuvant 
chemotherapy (fluorouracil/oxaliplatin), both clinically and ex vivo, in patients with locally advanced 
MMR-deficient (dMMR) rectal cancer.  Thus, induction systemic chemotherapy in dMMR locally 
advanced rectal cancer should be pursued with caution. In comparison, dMMR rectal tumors appear to 
be sensitive to chemoradiation. The vast majority of dMMR rectal tumors occur in the setting of Lynch 
syndrome, with an enrichment of MSH2 and MSH6 germline mutations.  To optimize treatment 
selection, all locally advanced rectal tumors should be screened for dMMR with subsequent genetic 








Purpose:  Evaluate response of mismatch repair deficient (dMMR) rectal cancer to neoadjuvant 
chemotherapy.  
Patients and Methods: dMMR rectal tumors at Memorial Sloan Kettering were retrospectively reviewed 
for characteristics, treatment, and outcomes. Fifty dMMR rectal cancer patients were identified by 
immunohistochemistry and/or microsatellite instability analysis, with initial treatment response 
compared to a matched pMMR rectal cancer cohort. Germline and somatic mutation analyses were 
evaluated. Patient-derived dMMR rectal tumoroids were assessed for chemotherapy sensitivity.  
Results: Of 21 patients receiving neoadjuvant chemotherapy (fluorouracil/oxaliplatin), 6 (29%) had 
progression of disease. In comparison, no progression was noted in 63 pMMR rectal tumors (P = 
0.0001). Rectal cancer dMMR tumoroids reflected this resistance to chemotherapy.  No genomic 
predictors of chemotherapy response were identified. Of 16 patients receiving chemoradiation, 13 
(93%) experienced tumor downstaging; one patient had stable disease, comparable to 48 pMMR rectal 
cancers. Of 13 patients undergoing surgery, 12 (92%) had early-stage disease. Forty-two (84%) of the 50 
patients tested positive for Lynch syndrome (LS) with enrichment of germline MSH2 and MSH6 
mutations when compared to 193 LS-associated colon cancer patients (MSH2, 57% vs 36%; MSH6, 17% 
vs 9%; P < .003).  
Conclusions: Over one-fourth of dMMR rectal tumors treated with neoadjuvant chemotherapy 
exhibited disease progression. Conversely, dMMR rectal tumors were sensitive to chemoradiation. MMR 
status should be performed upfront in all locally advanced rectal tumors with careful monitoring for 





Screening for deficient DNA mismatch repair (dMMR) is now recommended for all individuals with 
colorectal cancer (CRC) (1). While in colon cancers dMMR occurs in 15-20% of tumors, the prevalence of 
dMMR in rectal cancer is less frequent at ~10%. Microsatellite instability (MSI), the hallmark of dMMR 
tumors, may be caused by a germline mutation in one of the MMR genes (MLH1, MSH2, MSH6, PMS2 
and deletion of EPCAM), consistent with Lynch syndrome (LS)—or by epigenetic silencing of the MLH1 
promoter region (2). In colon cancer, dMMR tumors differ from MMR-proficient (pMMR) tumors in 
several aspects, including prognosis, response to treatment, and pattern of metastatic spread (3).  
 
Initial clinical differences in dMMR tumors were described in adjuvant studies of resected early stage 
CRCs where tumors exhibiting microsatellite instability (MSI/dMMR) were noted to have a favorable 
prognosis but no improvement with adjuvant 5-fluorouracil (5-FU)-based chemotherapy (4-7). The 
prognostic impact of dMMR appears to diminish with advancing disease stage, and the addition 
oxaliplatin to fluoropyrimidines seems to be associated with a survival benefit in stage III MSI/dMMR 
CRC (8,9). In the metastatic setting, dMMR/MSI is considerably less common, occurring in 3% to 5% of 
cases and, while data are sparse and inconsistent, dMMR tumors appear to be less responsive to 
chemotherapy (10-12). but have a similar response to chemoradiation (13). More recently, checkpoint 
inhibitors have demonstrated impressive responses in metastatic dMMR CRCs, as well as in other dMMR 
tumors (14,15).  
 
The prognostic and predictive role of MSI/dMMR in rectal cancer is not well characterized. In one study, 
dMMR rectal cancers appeared to have excellent prognosis with traditional trimodality therapy that 
included neoadjuvant chemoradiation, surgery, and adjuvant systemic chemotherapy (13). More 
recently, a shift in the treatment paradigm of locally advanced rectal cancer has resulted in a total 
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neoadjuvant approach (TNT), now incorporated into the National Comprehensive Cancer Network 
(NCCN) guidelines (1), wherein the sequencing of trimodality therapy is altered and is comprised of 
neoadjuvant systemic chemotherapy followed by chemoradiation and subsequent surgery (16-22). The 
efficacy of neoadjuvant systemic chemotherapy in dMMR rectal tumors, however, has not been 
investigated.  
 
Patients and Methods  
Patients 
After Institutional Review Board (IRB) approval, we retrospectively reviewed our Center’s clinical cancer 
database to identify patients with a diagnosis of dMMR CRC from 2003-2018. This study was conducted 
in accordance with the Declaration of Helsinki and all applicable laws. LS was defined as patients with a 
likely pathogenic or pathogenic germline mutation in a MMR gene. dMMR was determined by 
immunohistochemistry and/or MSI testing. MSI testing was performed either using a standard PCR-
based method or using targeted next-generation sequencing via MSISensor, a computational algorithm 
that analyzes sequencing reads at designated microsatellite regions in tumor-normal pairs (23). The 
distribution of germline mutations in the MMR genes was compared between LS-associated colon and 
LS-associated rectal cancer patients.  
 
Among dMMR or MSI-high CRCs, we then identified all those with rectal cancer as defined in the 
Supplement (22). Patients were divided into three groups based on initial treatment received. 
Treatment choice was dependent on staging, with clinical stage I patients proceeding directly to surgery. 
Patients with locally advanced rectal cancer underwent chemoradiotherapy prior to 2012 and TNT after 






 The TNT regimen included mFOLFOX which is described in the Supplement (24-26). Chemoradiation was 
administered as initial neoadjuvant therapy or commenced 2-4 weeks after completing neoadjuvant 
chemotherapy. Details of chemoradiation administration and scheduling are in the Supplement.  
 
Response to Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiation 
To assess the efficacy of neoadjuvant chemotherapy, we evaluated patients who underwent pre- and 
post-chemotherapy (before chemoradiation initiation) staging with rectal MRI and/or endorectal 
ultrasound and digital examination. Most, but not all, patients received all modalities of evaluation. For 
chemoradiation response, pathology specimens were evaluated for partial or complete pathologic 
response according to published criteria (27).  
 
Germline Analyses  
Clinical germline genetic analyses included full gene sequencing and multiplex ligation-dependent probe 
amplification analysis for large genomic rearrangement of the implicated DMA MMR gene(s) according 
to immunohistochemical staining patterns. For MLH1/PMS2 deficient tumors, germline analysis included 
the PMS2 and MLH1 genes while for MSH2/MSH6 deficient tumors, MSH2 and MSH6 were analyzed. For 
MSH2/MSH6 deficient tumors, once commercially available, 3’ deletions of the EPCAM gene and MSH2 
exons 1-7 inversion analysis were included.  
 
Molecular Analyses  
Archival formalin-fixed paraffin-embedded (FFPE) samples of 16 patients (18 samples) were analyzed by 
using an on-site cancer-associated gene bait capture, next generation sequencing (NGS) assay MSK-
9 
 
IMPACT, using a 341 to 468 gene-panel. The assay is capable of detecting mutations, small insertions 
and deletions, copy number alterations, and select structural rearrangements (28). Tumor tissue 
samples were obtained either pre or post treatment at the time of surgical resection or at development 
of metastatic disease. All subjects undergoing this molecular analysis via MSK-IMPACT provided written 
consent in the setting of a prospective IRB-approved institutional protocol.    
 
Comparison with Historical Controls 
Outcomes for the dMMR patients who received upfront chemotherapy or upfront chemoradiation were 
compared with outcomes for pMMR rectal cancer patients who received the same treatment modality 
matched for pre-treatment tumor and lymph node staging, based on our previously published study 
(17), by using a 3:1 pairing (upfront chemotherapy, 21 dMMR:63 pMMR; upfront chemoradiation, 16 
dMMR:48 pMMR). The pairings were selected chronologically from our existing database based upon 
previously published data (17). Baseline demographics were compared between the pMMR and dMMR 
cases. The spectrum of germline MMR mutations in LS-associated rectal cancer (n=42) was compared to 
all LS-associated colon cancer patients (n=193) using the Clinical Genetics LS database, which captures 
all patients undergoing germline testing for LS under an MSK IRB-approved protocol since 2004.  
 
Tumoroids 
Pre-treatment tumoroids were derived as described (29,30) from fresh rectal tumor samples and 
embedded in Matrigel. Tumoroids were validated by comparison to the rectal specimens from which 
they were derived via immunohistochemistry, targeted gene sequencing, and MMR staining to verify 
retention of alterations present in the original tumor. Drug treatments with FOLFOX were conducted as 
reported (29) with cell viability assessed using the CellTiter Glo assay (Promega, Madison Wi, USA) 
following kit protocol. Details on tumoroid treatment and analyses are provided in the Supplementary 
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Methods and have been previously published (29). All subjects from whom tumor tissue was used for 
tumoroid analysis provided written consent in the setting of a prospective IRB-approved institutional 
protocol.    
 
Statistical Analysis 
Continuous variables were compared using a two-tailed t test. Categorical variables were compared 
using 𝜒2 statistics or Fisher’s exact test, for limited sample sizes. P values < 0.05 were considered 
statistically significant. Tumoroid IC50 values with 95% confidence intervals were calculated as described 
in the Supplementary Methods and as previously described (29). Non-overlapping 95% confidence 
intervals were used to determine statistical significance with P < 0.05 (31). 
 
Results 
Patient and Tumor Characteristics 
Fifty patients met criteria of dMMR and/or MSI rectal adenocarcinoma with 25 having had IHC alone, 7 
MSI alone, and 18 having both IHC and MSI analysis. At diagnosis, 38 (76%) had locally advanced disease 
(stage II or III), 3 (6%) had metastatic disease, and 8 (16%) had stage I disease; one patient’s disease 
stage was unknown. Of the 50 patients, 21 (42%) received chemotherapy with fluorouracil and 
oxaliplatin as initial treatment, 16 (32%) received chemoradiation as initial treatment, and 13 (26%) 
proceeded directly to surgery (Fig 2a). The patients’ clinical and pathological characteristics are 
summarized in Table 1. 
 
Germline Genetic Characteristics  
11 
 
Of 50 patients, 42 (84%) had a LS-associated germline mutation in a MMR gene (Fig 1a). In LS patients, 
the prevalence of germline MSH2 and MSH6 mutations was significantly higher in the rectal (n=42) 
versus colon (n=193) cancer patients (rectal vs colon: MSH2: 57% vs 36%; MSH6: 17% vs 9%; P-value 
<0.003) (Fig 1b). The mean age at rectal cancer diagnosis in the LS patients (40.1 years) was equivalent 
to those without a germline mutation (45.6 years). Eleven (26%) of LS patients had a prior primary-
cancer diagnosis and 13 (31%) developed metachronous cancers. No prior or metachronous cancers 
were observed in the non-LS patients. The mechanism of dMMR in the 8 non-LS patients was found to 
be MLH1-promoter hypermethylation in 2 cases, double somatic mutation in 1 case, and unknown in 5 
cases. 
 
Initial Treatment with Neoadjuvant Chemotherapy  
Twenty-one patients, all meeting criteria for evaluation of response to induction chemotherapy, 
underwent pre- and post-chemotherapy staging with rectal MRI and/or endorectal ultrasound prior to 
chemoradiation(Fig 2b). Nineteen had locally advanced and two stage IV disease. Six (29%) of the 21 
patients had local disease progression, with symptoms including change in stool caliber (4) and return of 
rectal pain (2). Progression was confirmed by rectal MRI (4), CT (1), or endoscopic evaluation(1). Five of 
the six patients had LS with three harboring an MSH6 mutation. In the remaining 15 patients, tumor 
response was detected by MRI or endorectal examination. 
 
Seventeen of 21 patients who received initial chemotherapy were evaluable for response to subsequent 
neoadjuvant chemoradiation. Four (24%) of the 17 patients had a complete response (3 with 
pathological complete response, 1 clinical complete response), 11 (65%) had tumor downstaging (T, N, 
or both), 1 (6%) had stable disease, and 1 (6%) was upstaged. Of the four (19%) patients deemed not 
evaluable, one had inadequate baseline imaging, one had metastatic disease prior to treatment 
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initiation, and two did not receive chemoradiation (one declined due to fertility concerns). Of the two 
patients who did not receive chemoradiation, one had a complete pathologic response to FOLFOX and 
the other had disease progression with upstaging on pathologic examination. Details of patient TNM 
staging, treatment, and outcomes are outlined in Fig 2b.  
 
Eighteen (86%) of the 21 patients underwent total mesorectal excision. Of the three patients (14%) who 
did not undergo surgery, one had a clinical complete response and opted for watchful waiting, one had 
local disease progression while on FOLFOX, and one had metastatic progression in the peritoneum while 
on FOLFOX.  
 
Of the 6 (29%) patients whose disease progressed during induction FOLFOX therapy, four received 
neoadjuvant chemoradiation resulting in downstaging (2) and stable disease (2). The fifth patient did not 
receive chemoradiation due to peritoneal disease progression. The sixth patient declined 
chemoradiation for fertility preservation; this patient received three months of adjuvant FOLFIRI but 
experienced rapid progression of disease in the liver and peritoneum with eventual, long-term response 
to a checkpoint inhibitor (CPI) (Fig 2b). None of these six patients had a prior cancer diagnosis nor 
received chemotherapy prior to the diagnosis of rectal cancer.    
 
Initial Treatment with Neoadjuvant Chemoradiation  
Of 16 patients treated with initial neoadjuvant chemoradiation, 14 were evaluable for response and 13 
(93%) experienced tumor downstaging, 12 by pathological findings. Two patients (14%) experienced a 
pathologic complete response. Two patients did not undergo surgery due to complete clinical response. 
One patient did not undergo surgery due to synchronous liver disease. Two patients developed disease 
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recurrence and received immunotherapy with checkpoint inhibitors. The treatment course and outcome 
of these patients is outlined in Fig 2c. 
 
Initial Treatment with Surgical Resection 
Thirteen patients underwent upfront surgical resection; 8 due to clinical stage I disease and five for 
borderline stage I-II disease. The 12 lymph-node negative patients remain disease free, while 1 patient 
developed disease recurrence. Three received adjuvant chemoradiation. All patients are alive with a 
median follow up of 60 months (range 25-304). 
 
Comparison of Neoadjuvant Therapies with pMMR Historical Controls  
We next compared our dMMR rectal cancer patients who received upfront chemotherapy with our 
recently published pMMR rectal cancer cohort receiving the same neoadjuvant treatment (17). We 
sequentially evaluated 63 (3:1 pairing) pMMR patients and tabulated clinical and pathological 
characteristics and evaluated for response using the criteria described above Demographics for both the 
pMMR and dMMR cohorts are outlined in Supplementary Table 1. As expected, the dMMR rectal cancer 
patients reflect a younger cohort due to the presence of Lynch syndrome. However, no significant 
differences were noted in other baseline demographics including gender, race, or tumor grade.   In 
contrast to dMMR patients where 29% progressed on FOLFOX, none of the pMMR patients progressed 
on neoadjuvant chemotherapy and 89% had tumor downstaging (P-value = 0.0001) (Table 2). In a similar 
fashion, we compared dMMR rectal cancer patients receiving upfront chemoradiation to 48 (3:1 pairing) 
pMMR published historical controls. Of baseline demographics, again, only age was different in the 
pMMR and dMMR upfront chemoradiation groups (Supplementary Table 1). The pathologic response 




Recurrent and Persistent Disease  
Of the 50 patients, 9 experienced disease progression or recurrent disease. Six patients in the 
neoadjuvant chemotherapy cohort, two in the chemoradiation cohort, and one in the surgical cohort.  
Eight patients were treated with CPIs for persistent (2), locally recurrent (5), or metastatic disease (1). 
Remarkably, seven (88%) had significant response radiographically and all but one are alive with a mean 
follow up time from initiation of immunotherapy of 13 months (9-44 months). One patient with local 
disease recurrence had significant tumor response on a CPI, which has been sustained for >1 year (Fig 
3a). One patient developed rapidly progressive disease recurrence and died three weeks after receiving 
the first cycle of CPI (Fig 2a). One patient who was treated with upfront surgery developed a recurrence 
in the liver and underwent curative liver resection. 
 
Molecular Analyses 
Sixteen patients who received neoadjuvant chemotherapy as initial treatment had tissue samples 
available for genomic analyses. All but one patient had tumor sequencing performed on samples 
obtained after treatment from the resected tumor (n=11), a post treatment biopsy (n=1) or from a site 
of metastatic recurrence (n=4). No significant genomic differences, including tumor mutational burden, 
were found between responders to chemotherapy and non-responders. There were no BRAF mutations 
in the eight non-LS patients. (Fig 3b).  
 
Proof of principle chemosensitivity assay in patient-derived rectal cancer tumoroids  
To investigate the association between MMR status and chemoresistance in a biological model, pre-
treatment rectal cancer tumoroids were derived from pMMR and dMMR rectal tumors as previously 
described (29).  We tested the tumoroids for ex vivo sensitivity to FOLFOX to determine if our clinical 
observations would be reflected in the patient-derived tumoroids (29).  Indeed, in this proof of principle 
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assay, the dMMR rectal cancer tumoroids demonstrated significant resistance to FOLFOX compared to 
pMMR tumoroids (IC50 = 1.97 [95% CI 1.49-2.538] vs. 5.02 [95% CI 3.86-6.63], respectively; Fig 3c).  
 
Discussion 
Colon tumors exhibiting dMMR/MSI are biologically and clinically distinct; however, differences 
resulting from dMMR/MSI status specific to rectal cancers are not well-defined. In our study, 29% of 
dMMR/MSI locally advanced rectal tumors had disease progression on neoadjuvant chemotherapy, an 
alarmingly high rate compared to no progression in our large cohort of pMMR rectal tumors as well as 
published data from prospective studies of neoadjuvant therapy in locally advanced rectal cancer (32-
34). With the recent shift in the delivery of systematic chemotherapy in locally advanced rectal cancers 
from the adjuvant to the neoadjuvant setting (18-20,22), this observation has important clinical 
implications.  
Historically, dMMR/MSI has been both a prognostic and a predictive marker with dMMR/MSI 
portending a better prognosis in early-stage colorectal tumors, yet limited benefit from 
fluoropyrimidines (6,35,36). As the backbone of systemic therapy, fluoropyrimidine resistance raises 
concern for primary chemotherapy resistance in dMMR CRC patients. In fact, in the metastatic setting, 
small but well analyzed retrospective data consistently suggest that dMMR CRCs achieve inferior 
progression-free survival and response rates to chemotherapy compared to pMMR tumors (13). Further 
supporting our clinical findings are emerging data from the FoxTrot neoadjuvant colon cancer study, 
demonstrating a significantly worse response to neoadjuvant FOLFOX in dMMR versus pMMR colon 
tumors, with 75% of dMMR colon tumors exhibiting no pathologic response to chemotherapy.  As in our 




Studies of dMMR/MSI as a biomarker of radiation response have failed to demonstrate its 
predictive utility (38-40). Our finding, of a 93% response to neoadjuvant chemoradiation, is analogous to 
previously published dMMR rectal tumors (13) and similar to pMMR rectal cohorts (17). Notably, some 
patients with progression of disease on neoadjuvant chemotherapy achieved a subsequent response to 
chemoradiation, suggesting that at least a fraction of such patients may be salvaged with 
chemoradiation. However, as many locally advanced rectal cancer patients have bulky and clinically 
symptomatic tumors, prompt local control with selection of the optimal first-line treatment is 
imperative.  
While our somatic genomic analysis of dMMR rectal tumors did not identify any significant 
differences in genomic profiles among chemotherapy responders and non-responders, utilizing 
tumoroids derived from LS-associated dMMR rectal tumors, we were able to replicate the observed 
clinical resistance to FOLFOX. Additionally, our prior work has shown that dMMR rectal cancer 
tumoroids are exquisitely sensitive to radiotherapy (29). These patient-derived biological models of 
rectal cancer provide the means to study mechanisms of resistance to chemotherapy in real-time and 
could also help inform if an early change in therapy is indicated.  
 LS comprised a very high proportion (84%) of our dMMR rectal cancer patients, similar to the 
series by de Rosa et al (13). In contrast, approximately two-thirds of dMMR/MSI colon cancers are 
driven by epigenetic factors, most commonly MLH1 promoter hypermethylation (41,42). We also found 
that the distribution of germline MMR mutations varies in rectal versus colon cancer, with MSH2 and 
MSH6 mutations accounting for nearly 75% versus only 45% of LS-associated rectal cancer and colon 
cancer patients, respectively. Most studies have consistently demonstrated that CRC is more prevalent 
in MLH1 than MSH2 mutations carriers (2,16,17,25). As the majority of dMMR/MSI cancers arise in the 
proximal colon, and most prior studies have analyzed dMMR CRCs without distinguishing tumor location 
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(43,44), the high prevalence of LS in  dMMR rectal cancer may have inadvertently been masked. With 
increasing recognition of the biological importance of CRC sub-site stratification (45,46), whether dMMR 
rectal tumors portend a different tumor biology from right-sided dMMR tumors remains to be 
elucidated. Nonetheless, while a rare entity, the diagnosis of a dMMR rectal cancer in a patient should 
prompt referral for genetic testing and counseling given implications for cancer surveillance and risk-
reduction measures. 
In our analysis, patient derived organoid (PDO) models replicated the clinical resistance to 
FOLFOX chemotherapy in select dMMR/MSI cases. Our group, as well as others, have demonstrated the 
feasibility  of establishing PDOs in evaluating sensitivity to therapy (29,47,48). In locally advanced rectal 
cancer, PDOs may serve as an important test of sensitivity to other agents in select patients including 
chemoradiation (29) and irinotecan-based therapies (47).  Use of organoid models as ‘oracles of 
response prediction’ in dMMR and pMMR rectal cancers still requires additional validation and 
prospective testing, but our data suggest that it is possible and provides the first evidence of this 
potential utility in dMMR rectal patients.  
Universal tumor testing for markers of MMR deficiency is now endorsed for all CRC patients (1). 
However, our study also suggests that, in rectal cancer, MMR status should be determined prior to 
treatment initiation to allow for optimal selection of first-line treatment. Studies have demonstrated 
excellent concordance of IHC staining in matched biopsy and CRC resection samples (49), as well as 
concern that neoadjuvant treatment, especially chemoradiation, may cause inaccuracies in IHC analysis 
(50). As such, if tissue sample is inadequate from baseline colonoscopy biopsy, a repeat sampling of the 
rectal tumor prior to treatment initiation is appropriate.     
The inherent limitations of our study include its retrospective design, and the heterogeneity of 
disease stages and subsequent treatment approaches. However, we were able to separate treatment 
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modalities and evaluate response independently with comparison to unselected locally advanced pMMR 
rectal cancer patients who were receiving treatment at the same time, utilizing identical modalities, at 
the same institution. As dMMR rectal cancer is rare, prospective randomized studies are not feasible; 
however, large national studies like the PROSPECT trial (NCI 2012-00234) in locally advanced rectal 
cancer may help shed further light on the impact of MMR status on treatment response. Further studies 
of the etiology of chemoresistance via RNA analysis and epigenetic modification using dMMR tumors, 
organoids, and/or cell lines is clearly warranted. Furthermore, we noted a strong sustained response to 
CPIs in our patients with disease progression or recurrence, in line with the success of immunotherapy in 
advanced dMMR solid tumors. Trials of immunotherapy in early-stage dMMR colon cancer (ATOMIC 
NCT02912559) and in locally advanced rectal cancers are on-going or planned.  
In conclusion, our analyses demonstrate that induction chemotherapy is far less efficacious in 
dMMR than in pMMR rectal cancer, with over one-fourth of patients progressing while on induction 
chemotherapy. As such, our data strongly suggests that in dMMR rectal cancer patients, induction 
systemic chemotherapy should be undertaken with careful monitoring for tumor response, with close 
assessment of clinical symptoms. If concern is raised, prompt proctosigmoidoscopy or rectal MRI should 
be performed to evaluate for response and ensure a timely transition to chemoradiation. Additionally, 
given the importance of MMR status in the optimal selection of first-line treatment for locally advanced 
rectal cancer patients, MMR assessment should be performed at the time of rectal cancer diagnosis 
using biopsy samples, via IHC staining or MSI analysis, with subsequent germline genetic analysis in all 
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Characteristic No. (%) of Patients (n = 50) 





     Male 34 (68) 
     Female 16 (32) 
Race  
     White 39 (78) 
     Hispanic   3 (6) 
     Black   1 (2) 
     Asian   5 (10) 
     Ashkenazi Jewish   9 (18) 
     Not declared   2 (4) 
Histology  
     Well differentiated   0 (0) 
     Moderately differentiated 37 (74) 
     Poorly differentiated 10 (20) 
     Not available   3 (6) 
Clinical stage at diagnosis  
     I   8 (16) 
     II   8 (16) 
     III 30 (60) 
     IV   3 (6) 
     Not available   1 (2) 
First treatment for rectal cancer  
     Surgery 13 (26) 
     Chemoradiation 16 (32) 
     FOLFOX chemotherapy 21 (42) 
 






TABLE 2. Outcomes in Rectal Cancer Patients with dMMR or pMMR  
 
Outcome 
No. of Patients (%) 
dMMR  pMMR  
FOLFOX as initial treatment n = 21 n = 63 
   Progression of disease        6 (29) 0  
   Response or stable disease      15 (71) 63 (100) 
   
Chemoradiation as initial treatment n = 16 n = 48 
  Progression of disease        0          0 







Figure 1. Germline mutations in patients with Lynch syndrome. 
 
Figure 2. Overall study flow is demonstrated in (A). Patient characteristics, treatments, and outcomes 
for patients who received neoadjuvant FOLFOX chemotherapy (B) or chemoradiotherapy (ChemoRT) (C) 
as initial treatment. 5-FU, fluorouracil; CR, complete response; F/U, follow-up; NED, no evidence of 
disease; pCR, pathological complete response; PD, progression of disease; PR, partial response; SD, 
stable disease. 
 
Figure 3.  (A) Endoscopic imaging of a recurrent dMMR rectal adenocarcinoma pre and 5 and 8 months 
post treatment with pembrolizumab. (B) Oncoprint and tumor mutational burden in FOLFOX responders 
and non-responders with dMMR rectal adenocarcinoma. (C) Tumoroid ex vivo sensitivity to FOLFOX 
demonstrating relative sensitivity to FOLFOX in pMMR tumoroids and resistance in dMMR tumoroids 
with calculated IC50 values reported as 95% confidence intervals (IC50 = 1.97 [95% CI 1.49-2.538] vs. 
5.02 [95% CI 3.86-6.63], respectively; at left). At right, representative brightfield microscopy of 
tumoroids in 3D culture both pre (top micrographs) and post (bottom micrographs) treatment with 
FOLFOX chemotherapy from which the IC50 data was derived. Decreased confluence demonstrates 
relative, qualitative resistance to FOLFOX treatment in dMMR tumoroids compared with pMMR 
tumoroids.   



